Clinical trial • Phase I • Oncology
BIM2b for Glioblastoma
Phase I trial of BIM2b for Glioblastoma. None/Not specified-controlled. 36 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Glioblastoma
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 24-07-2024
- First CTIS Authorization Date
- 09-10-2024
Trial design
None/Not specified-controlled Phase I trial across 1 site in France.
- Comparator
- None/Not specified
- Target Sample Size
- 36
Recruitment
- Planned Sample Size
- 36
- Recruitment Window Months
- 24
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 36
France
- Earliest CTIS Part Ii Submission Date
- 05-09-2024
- Latest Decision Or Authorization Date
- 09-10-2024
- Processing Time Days
- 34
- Number Of Sites
- 1
- Number Of Participants
- 36
Sites
- Site Name
- Hopital D'Instruction Des Armees Percy
- Department Name
- Service de Neurologie
- Contact Person Name
- Ricard Damien
- Contact Person Email
- hia-percy-urc.contact.fct@def.gouv.fr
Sponsor
Primary sponsor
- Full Name
- Beta Innov
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- BIM2b
- First In Human
- Yes
Related trials
Other published trials that may interest you.